Cargando…

Sarcopenia: etiology, clinical consequences, intervention, and assessment

The aging process is associated with loss of muscle mass and strength and decline in physical functioning. The term sarcopenia is primarily defined as low level of muscle mass resulting from age-related muscle loss, but its definition is often broadened to include the underlying cellular processes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, T., Streeper, T., Cawthon, P., Baldwin, K., Taaffe, D. R., Harris, T. B.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832869/
https://www.ncbi.nlm.nih.gov/pubmed/19779761
http://dx.doi.org/10.1007/s00198-009-1059-y
_version_ 1782178346838261760
author Lang, T.
Streeper, T.
Cawthon, P.
Baldwin, K.
Taaffe, D. R.
Harris, T. B.
author_facet Lang, T.
Streeper, T.
Cawthon, P.
Baldwin, K.
Taaffe, D. R.
Harris, T. B.
author_sort Lang, T.
collection PubMed
description The aging process is associated with loss of muscle mass and strength and decline in physical functioning. The term sarcopenia is primarily defined as low level of muscle mass resulting from age-related muscle loss, but its definition is often broadened to include the underlying cellular processes involved in skeletal muscle loss as well as their clinical manifestations. The underlying cellular changes involve weakening of factors promoting muscle anabolism and increased expression of inflammatory factors and other agents which contribute to skeletal muscle catabolism. At the cellular level, these molecular processes are manifested in a loss of muscle fiber cross-sectional area, loss of innervation, and adaptive changes in the proportions of slow and fast motor units in muscle tissue. Ultimately, these alterations translate to bulk changes in muscle mass, strength, and function which lead to reduced physical performance, disability, increased risk of fall-related injury, and, often, frailty. In this review, we summarize current understanding of the mechanisms underlying sarcopenia and age-related changes in muscle tissue morphology and function. We also discuss the resulting long-term outcomes in terms of loss of function, which causes increased risk of musculoskeletal injuries and other morbidities, leading to frailty and loss of independence.
format Text
id pubmed-2832869
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-28328692010-03-15 Sarcopenia: etiology, clinical consequences, intervention, and assessment Lang, T. Streeper, T. Cawthon, P. Baldwin, K. Taaffe, D. R. Harris, T. B. Osteoporos Int Review The aging process is associated with loss of muscle mass and strength and decline in physical functioning. The term sarcopenia is primarily defined as low level of muscle mass resulting from age-related muscle loss, but its definition is often broadened to include the underlying cellular processes involved in skeletal muscle loss as well as their clinical manifestations. The underlying cellular changes involve weakening of factors promoting muscle anabolism and increased expression of inflammatory factors and other agents which contribute to skeletal muscle catabolism. At the cellular level, these molecular processes are manifested in a loss of muscle fiber cross-sectional area, loss of innervation, and adaptive changes in the proportions of slow and fast motor units in muscle tissue. Ultimately, these alterations translate to bulk changes in muscle mass, strength, and function which lead to reduced physical performance, disability, increased risk of fall-related injury, and, often, frailty. In this review, we summarize current understanding of the mechanisms underlying sarcopenia and age-related changes in muscle tissue morphology and function. We also discuss the resulting long-term outcomes in terms of loss of function, which causes increased risk of musculoskeletal injuries and other morbidities, leading to frailty and loss of independence. Springer-Verlag 2009-09-25 2010 /pmc/articles/PMC2832869/ /pubmed/19779761 http://dx.doi.org/10.1007/s00198-009-1059-y Text en © The Author(s) 2009 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Lang, T.
Streeper, T.
Cawthon, P.
Baldwin, K.
Taaffe, D. R.
Harris, T. B.
Sarcopenia: etiology, clinical consequences, intervention, and assessment
title Sarcopenia: etiology, clinical consequences, intervention, and assessment
title_full Sarcopenia: etiology, clinical consequences, intervention, and assessment
title_fullStr Sarcopenia: etiology, clinical consequences, intervention, and assessment
title_full_unstemmed Sarcopenia: etiology, clinical consequences, intervention, and assessment
title_short Sarcopenia: etiology, clinical consequences, intervention, and assessment
title_sort sarcopenia: etiology, clinical consequences, intervention, and assessment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832869/
https://www.ncbi.nlm.nih.gov/pubmed/19779761
http://dx.doi.org/10.1007/s00198-009-1059-y
work_keys_str_mv AT langt sarcopeniaetiologyclinicalconsequencesinterventionandassessment
AT streepert sarcopeniaetiologyclinicalconsequencesinterventionandassessment
AT cawthonp sarcopeniaetiologyclinicalconsequencesinterventionandassessment
AT baldwink sarcopeniaetiologyclinicalconsequencesinterventionandassessment
AT taaffedr sarcopeniaetiologyclinicalconsequencesinterventionandassessment
AT harristb sarcopeniaetiologyclinicalconsequencesinterventionandassessment